On August 4, 2020 Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage oncology therapeutics company developing drugs to treat cancers with the greatest medical need for new treatment options, including KRAS-mutated colorectal cancer, castration-resistant prostate cancer and leukemia, reported that the Company will participate in the BTIG Biotechnology Virtual Conference taking place August 10-11, 2020 (Press release, Cardiff Oncology, AUG 4, 2020, View Source [SID1234562780]).
Presenter: Dr. Mark Erlander, chief executive officer
Topic: KRAS Inhibition in Solid Tumors – Material Advancements and Continuing Challenges
Date: Monday, August 10, 2020
Time: 12:30 p.m. PT / 2:30 p.m. CT / 3:30 p.m. ET.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The discussion with Cardiff Oncology will focus on the Company’s oral and highly selective Polo-like Kinase 1 (PLK1) inhibitor, onvansertib, and its promise as a new therapeutic option in KRAS-mutated metastatic colorectal cancer, which has historically been a very challenging indication to effectively target and treat.
Conference attendees are welcome to join the fireside chat via the conference portal.